Up-to-date management of gout

Current Opinion in Rheumatology

Volumn 24, Issue 2, 2012, Pages 145-151

  Jordan, Kelsey M ^a  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

allopurinol; anti IL 1 inhibitor; febuxostat; gout; uricosuric

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; CANAKINUMAB; CLARITHROMYCIN; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DIURETIC AGENT; FEBUXOSTAT; INTERLEUKIN 1; LESINURAD; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PLACEBO; PROBENECID; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RASBURICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT URATE OXIDASE; RILONACEPT; SULFINPYRAZONE; TRIAMCINOLONE ACETATE; URATE; URICOSURIC AGENT;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALLERGENICITY; ARTHRALGIA; AVASCULAR NECROSIS; BLOOD DISEASE; BONE EROSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DAIRY PRODUCT; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DISABILITY; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EOSINOPHILIA; FLUID RETENTION; GOUT; HEART FAILURE; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INJECTION SITE INFECTION; INJECTION SITE REACTION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MYALGIA; MYOPATHY; NAUSEA; NEUROPATHY; OBESITY; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SOFT TISSUE DISEASE; SYSTEMATIC REVIEW (TOPIC); TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URIC ACID NEPHROPATHY; URIC ACID STONE; VASCULITIS; VITAMIN SUPPLEMENTATION; VOMITING;

DIET; GOUT; GOUT SUPPRESSANTS; HUMANS; LIFE STYLE; RISK FACTORS;

EID: 84857058348     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834ff637     Document Type: Review

References (39)

1. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67:906-966.
2. Mikuls TR, Farrar J, Bilker WB, et al. Gout epidemiology: Results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005; 64:267-272. (Pubitemid 40197509)
3. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guidelines for the management of gout. Rheumatology 2007; 46:1372-1374.
4. Zang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II. Management. Report task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324. (Pubitemid 44620440)
5. Rider TG, Jordan KM. The modern management of gout. Rheumatology 2010; 49:5-14.
6. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 2011; 23:192-202, 1531-6963.
7. Li S, Micheletti R. Role of diet in rheumatic disease. Rheum Dis Clin North Am 2011; 37:119-133.
8. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: A randomised controlled crossover trial. Ann Rheum Dis 2010; 69:1677-1682.
9. Dalbeth N, Ames R, Gamble G, et al. Daily intake of skim milk powder enriched with glycomacropeptide and G600 milk fat extract may reduce frequency of gout flares; results from a randomized, controlled trial. In: ACR Conference Proceedings; abstract 207; 2011. The first reported trial of a dietary intervention reducing urate levels.
10. Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: A meta-Analysis of randomized controlled trials. Arthritis Care Res 2011; 63:1295-1306.
11. Gaffo AL, Roseman JM, Jacobs DR Jr., et al. Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann Rheum Dis 2010; 69:1965-1970.
12. Choi HK, Willett W, Curhan G. Fructose rich beverages and risk of gout in women. JAMA 2010; 304:2270-2278.
13. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 2006; 12:275-276. (Pubitemid 44915324)
14. Khanna P, Singh MK, Fitzgerald JD, et al. Pharmacological treatment of acute gout: A systematic review. In: ACR Conference Proceedings, abstract 1025; 2011.
15. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006; 8:S1.
16. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143:499-516. (Pubitemid 41379398)
17. Terkeltaub R, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060-1068.
18. Van der Velden W, Hussen J, ter Laak H, de Sevaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: The role of clarithromycin. J Med 2008; 66:204-206.
19. Terkeltaub R, Furst D, DiGiacinto J, et al. A one sequence, two-period pharmacokinetic drug-drug interaction study with colchicine reveals profound effects of clarithromycin (a macrolide antibiotic) on the pharmacokinetic profile of colchicine in healthy adults. In: ACR Conference Proceedings; abstract 1946; 2008.
20. Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 15:71-78. (Pubitemid 47259281)
21. Janssens HJ, Lucassen PLBJ, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008; Issue 2. Art. No. CD005521.
22. McGonagle D, Tan AL, Shankaranarayana S, et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007; 66:1683-1684. (Pubitemid 350205463)
23. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
24. Brown JP, So A, Dikranian A, et al. Long-term efficacy and safety of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients. In: ACR Conference Proceedings; abstract 1016; 2011.
25. So A, Alten R, Schumacher HR, et al. Inflammation suppression over 24 weeks in patients with gouty arthritis: Results from two phase-III core and extension studies comparing canakinumab with triamcinolone acetonide. In: ACR Conference Proceedings; abstract 1019; 2011.
26. Terkeltaub R, Schumacher HR, Mitha E, et al. Integrated safety analysis of four trials of interleukin-1 blockade with rilonacept for gout flare prevention in patients taking uric acid-lowering therapy. In: ACR Conference Proceedings; abstract 1015; 2011.
27. Schumacher HR, Evans RR, Birbara CA, et al. Rilonacept for prevention of gout flares associated with uric acid-lowering therapy: Response rate across three phase 3 clinical trials. In: ACR Conference Proceedings; abstract 1024; 2011.
28. Stamp LK, Taylor W, Jones PBB. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: A proposed nomogram for safe starting dosing of allopurinol. In: ACR Conference Proceedings; abstract 2579; 2011.
29. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-2461. (Pubitemid 41781828)
30. Schumacher HR Jr., Baker M, Lloyd E, et al. Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study. Rheumatology 2009; 48:188-194.
31. Reinders MK, van Roon EN, Jansen TL. Efficacy and tolerability of uratelowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68:51-56.
32. Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and safety of Lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol refractory gout patients: Randomised, double-blind, placebo-controlled, phase 2b study. In: EULAR Conference Proceedings; abstract OPO111; 2011. A novel uricosuric agent.
33. Bleyer A, Hurt TC. Genetic factors associated with gout and hyperuricemia. Adv Chronic Kidney Dis 2006; 13:124-130.
34. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumour lysis syndrome and in gout. Int J Med Sci 2007; 2:83-93. (Pubitemid 46434125)
35. Schumacher HR, Chen LX. Newer therapeutic approaches: Gout. Rheum Dis Clin North Am 2006; 32:235-244. (Pubitemid 43292534)
36. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005; 20:431-433. (Pubitemid 40276903)
37. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60:59-68. (Pubitemid 350186186)
38. Sundy J, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatments. Two randomised trials. JAMA 2011; 306:711-720.
39. Khanna PP, Perex-Ruiz F, Maranian P, Khanna D. Long term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form 36 is responsive to change in chronic gout. Rheumatology 2011; 50:740-745.